Eli Lilly and Company (LLY) Revenue by Segment
Eli Lilly and Company revenue by segment at a glance
In Q3 fiscal 2018 (the quarter ended September 30, 2018), Eli Lilly and Company's largest business segment was Human Pharmaceutical Products, with $5.29 billion or 87% of revenue, up 7.6% from a year earlier. Next: Animal Health Products (13%).
By product or service, Cardiometabolic Health brought in 80%, Oncology brought in 11% and Immunology brought in 6% of revenue in Q2 fiscal 2026.
By region, United States brought in 63%, Europe brought in 18% and Rest of World brought in 13% of revenue in Q2 fiscal 2026.
The fastest-growing business segment from a year earlier was Human Pharmaceutical Products (+7.6%).
From company filings, in USD; latest quarter ended September 30, 2018; quarterly data from Q3 fiscal 2017.
Eli Lilly and Company
Revenue breakdown
Fiscal quarters, from company filings
Eli Lilly and Company revenue by business segment, last 4 quarters
| Business segment | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Human Pharmaceutical Products | – | – | – | – | 87% |
| Animal Health Products | – | – | – | – | 13% |
In USD, fiscal quarters as reported; share = part of Q3 FY18 revenue.
Eli Lilly and Company revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Cardiometabolic Health | $18.4B | $15.8B | $13.2B | $11.3B | 80% |
| Oncology | $2.6B | $2.3B | $2.4B | $2.4B | 11% |
| Immunology | $1.4B | $1.2B | $1.4B | $1.3B | 6% |
| Neuroscience | $429.0M | $382.0M | $315.7M | $344.0M | 2% |
| Other | $205.0M | $187.0M | – | $202.0M | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Eli Lilly and Company revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $14.4B | $12.1B | $11.3B | $10.8B | 63% |
| Europe | $4.1B | $3.6B | $3.5B | $2.6B | 18% |
| Rest of World | $2.9B | $2.8B | $1.7B | $1.2B | 13% |
| China | $941.0M | $693.0M | $560.4M | $466.0M | 4% |
| Japan | $628.0M | $571.0M | $554.7M | $521.0M | 3% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
What are Eli Lilly and Company's business segments?
Human Pharmaceutical Products and Animal Health Products (as reported for Q3 fiscal 2018).
Which business segment makes the most money for Eli Lilly and Company?
Human Pharmaceutical Products: $5.29 billion, or 87% of revenue, in Q3 fiscal 2018.
What are Eli Lilly and Company's main products and services?
By revenue in Q2 fiscal 2026: Cardiometabolic Health (80%), Oncology (11%), Immunology (6%) and Neuroscience (2%).
Where does Eli Lilly and Company make its money?
By region in Q2 fiscal 2026: United States (63%), Europe (18%), Rest of World (13%) and China (4%).
